Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $552.00 MXN
Change Today 0.00 / 0.00%
Volume 0.0
AZNN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 4:09 PM 08/19/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

on agreement with AstraZeneca, along with MedImmune, its global biologics research and development arm, to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanized IgG4 antibody. In April 2015, AstraZeneca and MedImmune announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma. In May 2015, AstraZeneca plc and MedImmune, have entered into a collaboration with Innate Pharma SA to develop Innate's anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. In May 2015, The Montreal Heart Institute announced a collaboration with AstraZeneca to screen 80,000 samples for cardiovascular and diabetes genetic associated with cardiovascular diseases and diabetes, their complications and treatment outcomes. In May 2015, AstraZeneca (UK) has entered into a collaboration deal with Abbott for developing companion diagnostic tests in order to identify patients with severe asthma, who are highly likely to benefit from a candidate drug, tralokinumab. In May 2015, Astrazeneca (AZN) and Eli Lilly & Co. (LLY) said that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA), Eli Lilly's VEGF Receptor 2 antiangiogenic cancer medicine. In June 2015, AstraZeneca has launched a research and development (R&D) respiratory centre in the Spanish city of Barcelona. In July 2015, AstraZeneca and the University of Adelaide have announced an exciting new collaboration which will see 50 of AstraZeneca’s drug compounds passed to university researchers to study new therapies. In July 2015, Innate Pharma SA announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, received HSR clearance. In July 2015, Fujifilm Kyowa Kirin Biologics Co. Ltd. announced that it has entered into an agreement with AstraZeneca plc to establish a joint venture for the development and commercialisation of FKB238 in development for the treatment of multiple solid tumours. In July 2015, Charles River Laboratories International reported the extension of its strategic drug development partnership with AstraZeneca. Under the agreement, Charles River Laboratories International has extended its initial three-year partnership with AstraZeneca for an additional five-year period. In August 2015, Isis Pharmaceuticals, Inc. and AstraZeneca announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. In August 2015, AstraZeneca has signed a licencing agreement with Heptares Therapeutics to develop novel immuno-oncology treatments. In August 2015, AstraZeneca PLC and Peregrine Pharmaceuticals, Inc. announced that they have entered into a cancer immunotherapy clinical trial collaboration. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNN:MM $552.00 MXN 0.00

AZNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $141.74 USD +0.50
Abbott Laboratories $44.14 USD -0.10
Biogen Inc $301.63 USD -2.58
Eli Lilly & Co $81.60 USD -0.21
Valeant Pharmaceuticals International Inc C$301.25 CAD -6.75
View Industry Companies
 

Industry Analysis

AZNN

Industry Average

Valuation AZNN Industry Range
Price/Earnings 67.5x
Price/Sales 3.2x
Price/Book 4.4x
Price/Cash Flow 67.5x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.